NCT06495125 2025-04-17Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerEmory UniversityPhase 2 Recruiting50 enrolled